var data={"title":"Factor VIII, recombinant human: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Factor VIII, recombinant human: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5650?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=factor-viii-recombinant-human-patient-drug-information\" class=\"drug drug_patient\">see &quot;Factor VIII, recombinant human: Patient drug information&quot;</a> and <a href=\"topic.htm?path=factor-viii-recombinant-human-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Factor VIII, recombinant human: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135784\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Advate;</li>\n      <li>Afstyla;</li>\n      <li>Helixate FS;</li>\n      <li>Kogenate FS;</li>\n      <li>Kogenate FS Bio-Set;</li>\n      <li>Kovaltry;</li>\n      <li>Novoeight;</li>\n      <li>Nuwiq;</li>\n      <li>Recombinate;</li>\n      <li>Xyntha;</li>\n      <li>Xyntha Solofuse</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135785\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Advate;</li>\n      <li>Helixate FS;</li>\n      <li>Kogenate FS;</li>\n      <li>Kovaltry;</li>\n      <li>Nuwiq;</li>\n      <li>Xyntha;</li>\n      <li>Xyntha Solofuse</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135799\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antihemophilic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135786\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hemophilia A:</b> IV: Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment. In general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2 units/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Control and prevention of bleeding episodes or perioperative management:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling:</i> Refer to manufacturer&rsquo;s labeling for specific recommendations; varies by product.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate recommendations (WFH [Srivastava 2013]):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage based on desired factor VIII increase (%):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">To calculate dosage needed based on desired factor VIII increase (%):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">[Body weight (kg) x desired factor VIII increase (%)] divided by 2 (%/units/kg) = units factor VIII required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">For example:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">50 kg x 30 (% increase) divided by 2 = 750 units factor VIII</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage based on expected factor VIII increase (%):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">It is also possible to calculate the <b>expected</b> % factor VIII increase:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">[# units administered x 2 (%/units/kg)] divided by body weight (kg) = expected % factor VIII increase</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">For example:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">[1,400 units x 2] divided by 70 kg = 40%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>World Federation of Hemophilia (WFH) treatment recommendations when no significant resource constraint exists (WFH [Srivastava 2013]): </b></p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">2013 World Federation of Hemophilia Treatment Recommendations (When No Significant Resource Constraint Exists)</caption>\n      <col></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Site of Hemorrhage/Clinical Situation</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Desired Factor VIII Level to Maintain</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Duration</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"3\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <b>Note:</b> Factor VIII level may either be expressed as units/dL or as %. Dosing frequency most commonly corresponds to the half-life of factor VIII but should be determined based on an assessment of factor VIII levels before the next dose.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Joint</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">40 to 60 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 to 2 days, may be longer if response is inadequate</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Superficial muscle/no neurovascular compromise</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">40 to 60 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 to 3 days, sometimes longer if response is inadequate</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Iliopsoas and deep muscle with neurovascular injury, or substantial blood loss</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 80 to 100 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 1 to 2 days</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 30 to 60 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 3 to 5 days, sometimes longer as secondary prophylaxis during physiotherapy</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">CNS/Head</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 80 to 100 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 1 to 7 days</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 50 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 8 to 21 days</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Throat and neck</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 80 to 100 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 1 to 7 days</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 50 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 8 to 14 days</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Gastrointestinal</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 80 to 100 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 7 to 14 days</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 50 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> Not specified</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Renal</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 to 5 days</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Deep laceration</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5 to 7 days</p></td></tr>\n        <tr>\n          <td rowspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Surgery (major)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Preop:</i> 80 to 100 units/dL</p></td>\n          <td align=\"center\"></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 60 to 80 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 1 to 3 days</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 40 to 60 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 4 to 6 days</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 30 to 50 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 7 to 14 days</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Surgery (minor)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Preop:</i> 50 to 80 units/dL</p></td>\n          <td align=\"center\"></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 30 to 80 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 1 to 5 days depending on procedure type</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Continuous infusion (for patients who require prolonged periods of treatment [eg, intracranial hemorrhage or surgery] to avoid peaks and troughs associated with intermittent infusions) </i>(Batorova 2002; Batorova 2012; Poon 2012; Rickard 1995; WFH [Srivastava 2013]): Following initial bolus to achieve the desired factor VIII level, initiate 2 to 4 units/kg/hour; adjust dose based on frequent factor assays and calculation of factor VIII clearance at steady-state using the following equations:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Factor VIII clearance (mL/kg/hour) = (current infusion rate in units/kg/hour) divided by (plasma level in units/mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">New infusion rate (units/kg/hour) = (factor VIII clearance in mL/kg/hour) x (desired plasma level in units/mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Routine prophylaxis to prevent or reduce the frequency of bleeding episodes:</b> <b>Note: </b>Maintain factor VIII trough levels between 1% and 5% as clinically indicated (Collins 2011; Rossbach 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Advate:</i> 20 to 40 units/kg every other day (3 to 4 times weekly). Alternatively, an every-third-day dosing regimen may be used to target factor VIII trough levels of &ge;1%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Afstyla:</i> 20 to 50 units/kg 2 to 3 times weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Helixate FS:</i> 25 units/kg 3 times weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Kogenate FS:</i> 25 units/kg 3 times weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Kovaltry:</i> 20 to 40 units/kg 2 or 3 times weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Novoeight:</i> 20 to 50 units/kg 3 times weekly <b>or</b> 20 to 40 units/kg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Nuwiq:</i> 30 to 40 units/kg every other day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135795\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=factor-viii-recombinant-human-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Factor VIII, recombinant human: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hemophilia A:</b> Children and Adolescents: IV: Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment. In general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2 units/dL. Children &lt;6 years may require higher doses and/or more frequent administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Control and prevention of bleeding episodes or perioperative management:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Routine prophylaxis to prevent bleeding episodes: Note:</b> Maintain factor VIII trough levels between 1% and 5% as clinically indicated (Collins 2011; Rossbach 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Advate:</i> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Afstyla:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;12 years: 30 to 50 units/kg 2 to 3 times weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Kovaltry:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &le;12 years: 25 to 50 units/kg twice weekly, 3 times weekly, or every other day according to individual requirements.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Novoeight:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;12 years: 25 to 60 units per kg 3 times weekly <b>or</b> 25 to 50 units/kg every other day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Nuwiq:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to 11 years: 30 to 50 units/kg every other day or 3 times weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Routine prophylaxis to prevent bleeding episodes and joint damage (in patients without preexisting joint damage):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Helixate FS, Kogenate FS:</i> Infants, Children, and Adolescents: 25 units/kg every other day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135787\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673189\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673190\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135770\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kogenate FS: 250 units, 500 units, 1000 units [contains mouse (murine) and/or hamster protein]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Afstyla: 250 units, 500 units, 1000 units, 1500 units, 2000 units, 2500 units, 3000 units [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Helixate FS: 250 units, 500 units, 1000 units, 2000 units, 3000 units [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kogenate FS: 2000 units, 3000 units [contains mouse (murine) and/or hamster protein]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kogenate FS Bio-Set: 250 units, 500 units, 1000 units, 2000 units, 3000 units [contains mouse (murine) and/or hamster protein]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nuwiq: 250 units, 500 units, 1000 units, 2000 units, 2500 units, 3000 units, 4000 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xyntha: 250 units, 500 units, 1000 units, 2000 units [albumin free; contains mouse (murine) and/or hamster protein, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xyntha Solofuse: 250 units, 500 units, 1000 units, 2000 units, 3000 units [albumin free; contains mouse (murine) and/or hamster protein, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kovaltry: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 2000 units (1 ea); 3000 units (1 ea) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Advate: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 1500 units (1 ea); 2000 units (1 ea); 3000 units (1 ea); 4000 units (1 ea) [albumin free; contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Novoeight: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 1500 units (1 ea); 2000 units (1 ea); 3000 units (1 ea) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nuwiq: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 2000 units (1 ea); 2500 units (1 ea); 3000 units (1 ea); 4000 units (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Recombinate: 220-400 units (1 ea); 401-800 units (1 ea); 801-1240 units (1 ea); 1241-1800 units (1 ea); 1801-2400 units (1 ea) [contains albumin human, polyethylene glycol, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135756\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25573579\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strengths expressed with approximate values.  Consult individual vial labels for exact potency within each vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135773\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Use administration sets/tubing provided by manufacturer (if provided). Rate of administration should be determined by patient tolerability (maximum rates vary by product).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Advate: Infuse over &le;5 minutes (maximum: 10 mL/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Afstyla: Infuse up to a maximum rate of 10 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Helixate FS, Kogenate FS, Kovaltry: Infuse over 1 to 15 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Novoeight: Infuse slowly over 2 to 5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Nuwiq: Infuse up to a maximum rate of 4 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Recombinate reconstituted with 5 mL of SWFI: Infuse up to a maximum rate of  5 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Recombinate reconstituted with 10 mL of SWFI: Infuse up to a maximum rate of 10 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Xyntha, Xyntha Solufuse: Infuse over several minutes. Do not admix or administer in same tubing as other medications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">According to the World Federation of Hemophilia (WFH), infuse by slow IV injection at a rate not to exceed 3 mL/minute (adults) or 100 <b>units</b>/minute (young children); may also administer as a continuous infusion in select patients (WFH [Srivastava 2013]). When administering as a continuous infusion, may use a portable mini-pump or syringe pump (Batorova 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135772\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemophilia A: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Control and prevention of bleeding episodes:</b> Prevention and control of bleeding episodes in adults and children with hemophilia A.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Perioperative management:</b> Surgical prophylaxis in adults and children with hemophilia A.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Routine prophylaxis to prevent or reduce the frequency of bleeding:</b> Routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Routine prophylaxis to prevent bleeding episodes and joint damage (Helixate FS, Kogenate FS):</b> Routine prophylactic treatment to reduce the frequency of bleeding episodes and the risk of joint damage in children without preexisting joint damage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Not indicated for the treatment of von Willebrand disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6814324\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Factor VIII may be confused with Factor XIII</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Confusion may occur due to the omitting of  &ldquo;Factor VIII&rdquo; from some product labeling. Review product contents carefully prior to dispensing any antihemophilic factor.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135763\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Actual frequency may vary by product.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (7% to 26%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (&le;16%), skin rash (&le;16%), urticaria (&le;16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (6% to 13%), vomiting (7% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Increased factor VIII inhibitors (&le;20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Catheter infection (18% to 19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (8% to 25%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (11% to 19%), nasopharyngitis (17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&le;43%; in patients previously exposed to factor VIII products: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest discomfort (1%), palpitations (1%), sinus tachycardia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Pain (8%), procedural pain (5%), insomnia (3%), chills (&le;1%), dizziness (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Allergic dermatitis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (5% to 8%), abdominal distress (2%), abdominal pain (2%), dyspepsia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Lymphadenopathy (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased liver enzymes (in patients previously exposed to factor VIII products: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: injection site reaction (3% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (5% to 7%), back pain (&le;3%; more common in children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otic infection (&le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngolaryngeal pain (9%), upper respiratory tract infection (9%), nasal congestion (8%), rhinorrhea (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Limb injury (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, anorexia, catheter complication (venous catheter access), chest discomfort, cold extremities, cyanosis, drowsiness, dysgeusia, edema, epistaxis, erythema, facial edema, facial flushing, fatigue, feeling hot, flushing, hematoma, hot flash, hyperhidrosis, hypotension, inflammation at injection site, joint swelling, laryngeal edema, limb pain, loss of consciousness, maculopapular rash, malaise, myalgia, pain at injection site, pallor, paresthesia, restlessness, tachycardia, tremor, vasodilatation, vertigo, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135776\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, anaphylaxis) to antihemophilic factor, mouse or hamster protein (Advate, Afstyla, Helixate FS, Kogenate FS, Kovaltry, Novoeight, Recombinate, Xyntha), bovine protein (Recombinate only), or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135760\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Antibody formation: The development of factor VIII antibodies has been reported with antihemophilic factors; monitor for signs of formation of antibodies to factor VIII; may occur at any time but more common in young children with severe hemophilia. Suspect factor VIII antibodies if the plasma factor VIII level does not increase as expected or if bleeding is not controlled after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Allergic hypersensitivity reactions (including anaphylaxis) may occur; discontinue if hypersensitivity symptoms occur and administer appropriate treatment. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Albumin: Recombinate is stabilized using human albumin. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bovine: Recombinate may contain bovine protein.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Mouse/hamster protein:  Some products may contain trace amounts of mouse or hamster protein.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sucrose: Some products are stabilized with or may contain sucrose. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; von Willebrand factor: Some products contain naturally-occurring von Willebrand factor for stabilization; however, efficacy has not been established for the treatment of von Willebrand disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dose requirements: The dosage requirement will vary in patients with factor VIII inhibitors; optimal treatment should be determined by clinical response.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298758\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6218001\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9723&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Emicizumab-kxwh: May enhance the thrombogenic effect of Factor VIII Products.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135766\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135778\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Factor VIII concentrations may increase in pregnant women with coagulation disorders. Pregnant women should have clotting factors monitored, particularly at 28 and 34 weeks gestation and prior to invasive procedures. Prophylaxis may be needed if concentrations are &lt;50 units/mL at term and treatment should continue for 3 to 5 days postpartum depending on route of delivery. Because parvovirus infection may cause hydrops fetalis or fetal death, a recombinant product is preferred if prophylaxis or treatment is needed. The neonate may also be at an increased risk of bleeding following delivery and should be tested for the coagulation disorder (Kadir 2009; Lee 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20547295\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if antihemophilic factor (recombinant) is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000257\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135768\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate and blood pressure (before and during IV administration); plasma factor VIII activity prior to and during treatment; development of factor VIII inhibitors; signs of bleeding; hemoglobin, hematocrit; hypersensitivity reactions </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When administering as a continuous infusion, monitor frequently for pump failure (WFH [Srivastava 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135771\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Classification of hemophilia; normal is defined as 1 unit/mL of factor VIII</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Severe: Factor level &lt;1% of normal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Moderate: Factor level 1% to 5% of normal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Mild: Factor level &gt;5% to &lt;40% of normal</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135759\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Factor VIII replacement, necessary for clot formation and maintenance of hemostasis. It activates factor X in conjunction with activated factor IX; activated factor X converts prothrombin to thrombin, which converts fibrinogen to fibrin, and with factor XIII forms a stable clot.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135775\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>: ~0.4 to 0.85 dL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Advate: Children &lt;12 years: 8.7 to 11.2 hours; Adolescents and Adults: 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Afstyla: Children &lt;12 years: 10.2 to 10.4 hours; Children &ge;12 years and Adolescents: 14.3 hours; Adults: 14.2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Helixate FS, Kogenate FS: Children: 10.7 hours; Adults: 13.7 to 14.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Kovaltry: Children &lt;12 years: ~12 hours; Children &ge;12 years, Adolescents, and Adults: ~14 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Novoeight: Children &lt;12 years: 7.7 to 10 hours; Adolescents and Adults: 11 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nuwiq: Children &le;12 years: 11.9 to 13.1 hours; Adolescents and Adults: 17.1 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Recombinate: Adults: 14.6 &plusmn; 4.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Xyntha, Xyntha Solofuse: Children and Adolescents: 6.9 to 8.3 hours; Adults: 11 to 17 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21121604\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Afstyla Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1500 unit (Price provided is per AHF Unit): $1.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $1.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2500 unit (Price provided is per AHF Unit): $1.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (Price provided is per AHF Unit): $1.98</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Helixate FS Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $1.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (Price provided is per AHF Unit): $1.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Kogenate FS Bio-Set Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $1.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (Price provided is per AHF Unit): $1.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Kogenate FS Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $1.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (Price provided is per AHF Unit): $1.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Nuwiq Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2500 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4000 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Xyntha Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Xyntha Solofuse Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Advate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1500 unit (Price provided is per AHF Unit): $1.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $1.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (Price provided is per AHF Unit): $1.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4000 unit (Price provided is per AHF Unit): $1.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Kovaltry Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (1): $2.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $2.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (1): $2.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (1): $2.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (1): $2.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (1): $2.09</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Novoeight Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $2.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $2.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $2.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1500 unit (Price provided is per AHF Unit): $2.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $2.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (Price provided is per AHF Unit): $2.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Nuwiq Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2500 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4000 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Recombinate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">220-400 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">401-800 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">801-1240 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1241-1800 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1801-2400 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135779\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Advate (AR, AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FR, GB, GR, HK, HR, HU, IE, IS, IT, JP, KR, LT, MT, MY, NL, NO, NZ, PT, QA, RO, SE, SG, SI, SK);</li>\n      <li>Green Eight (KR);</li>\n      <li>Green VIII (LK);</li>\n      <li>Greenmono (KR);</li>\n      <li>Helixate (AT, GR, HU, IT, NL, PL);</li>\n      <li>Helixate Nexgen (AU, BE, CZ, DE, DK, EE, ES, FR, NO, SE);</li>\n      <li>Helixate NexGen (GB, IE);</li>\n      <li>Kogenate (AT, BE, CH, CL, CY, CZ, DE, DK, EE, ES, FR, GB, GR, HR, HU, IE, IT, JO, LT, LU, MT, NL, NO, NZ, PL, PT, SE, SI, TW);</li>\n      <li>Kogenate FS (AE, AR, AU, CN, CO, CR, EC, GT, HK, HN, ID, IL, LB, MY, PA, QA, SA, SG, SV, TH, ZA);</li>\n      <li>Kryobulin TIM 3 (HN);</li>\n      <li>Logenate (RO);</li>\n      <li>Octanate (ID, MY);</li>\n      <li>Recombinate (AR, AT, AU, BE, BG, BR, CH, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IL, IT, LT, NL, NZ, QA, SE, TH);</li>\n      <li>Refacto (AT, CY, CZ, GR, HU, IT, NL, PL);</li>\n      <li>Refacto AF (BE, CH, DE, DK, EE, FR, GB, NO, SE);</li>\n      <li>Xyntha (AR, AU, CL, KR, NZ, SA, SG, TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Advate (antihemophilic factor [recombinant]) [prescribing information]. Westlake Village, CA: Baxter Healthcare Corporation; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Afstyla (antihemophilic factor [recombinant]) [prescribing information]. Kankakee, IL: CSL Behring LLC; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Afstyla (antihemophilic factor [recombinant]) [product monograph]. Ottawa, Ontario, Canada: CSL Behring LLC; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Batorova A, Holme P, Gringeri A, et al; European Haemophilia Treatment Standardisation Board. Continuous infusion in haemophilia: current practice in Europe. <i>Haemophilia</i>. 2012;18(5):753-759.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-drug-information/abstract-text/22530687/pubmed\" target=\"_blank\" id=\"22530687\">22530687</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Batorova A, Martinowitz U. Continuous infusion of coagulation factors. <i>Haemophilia</i>. 2002;8(3):170-177.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-drug-information/abstract-text/12010406/pubmed\" target=\"_blank\" id=\"12010406\">12010406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Collins PW, Fischer K, Morfini M, Blanchette VS, Bj&ouml;rkman S; International Prophylaxis Study Group Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. <i>Haemophilia.</i> 2011;17(1):2-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-drug-information/abstract-text/20731726/pubmed\" target=\"_blank\" id=\"20731726\">20731726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Helixate FS (antihemophilic factor [recombinant]) [prescribing information]. Kankakee, IL: CSL Behring LLC; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kadir R, Chi C, Bolton-Maggs P. Pregnancy and rare bleeding disorders. <i>Haemophilia</i>. 2009;15(5):990-1005. doi: 10.1111/j.1365-2516.2009.01984.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-drug-information/abstract-text/19298378/pubmed\" target=\"_blank\" id=\"19298378\">19298378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kogenate FS (antihemophilic factor [recombinant]) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kogenate FS with Bio-Set (antihemophilic factor [recombinant]) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kovaltry (antihemophilic factor [recombinant]) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee CA, Chi C, Pavord SR, et al. The obstetric and gynaecological management of women with inherited bleeding disorders--review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization. <i>Haemophilia</i>. 2006;12(4):301-336.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-drug-information/abstract-text/16834731/pubmed\" target=\"_blank\" id=\"16834731\">16834731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lusher JM, &ldquo;Transfusion Therapy in Congenital Coagulopathies,&rdquo; <i>Hematol Oncol Clin North Am</i>, 1994, 8(6):1167-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-drug-information/abstract-text/7860443/pubmed\" target=\"_blank\" id=\"7860443\">7860443</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Manucci PM, &ldquo;Impact of Recombinant Factor VIII on Hemophilia Care,&rdquo; <i>Vox Sang</i>, 1994, 67(Suppl 3):49-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-drug-information/abstract-text/7975511/pubmed\" target=\"_blank\" id=\"7975511\">7975511</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nilsson IM, Berntorp E, Lofqvist T, et al, &ldquo;Twenty-five Years' Experience of Prophylactic Treatment in Severe Haemophilia A and B,&rdquo; <i>J Intern Med</i>, 1992, 232(1):25-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-drug-information/abstract-text/1640190/pubmed\" target=\"_blank\" id=\"1640190\">1640190</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Novoeight (antihemophilic factor [recombinant]) [prescribing information]. Plainsboro, NJ: Novo Nordisk; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nuwiq (antihemophilic factor [recombinant]) [prescribing information]. Hoboken, NJ: Octapharma; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poon MC, Card R. Hemophilia management in transfusion medicine. <i>Transfus Apher Sci</i>. 2012;46(3):299-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-drug-information/abstract-text/22503305/pubmed\" target=\"_blank\" id=\"22503305\">22503305</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Recombinate (antihemophilic factor [recombinant]) [prescribing information]. Westlake Village, CA: Baxalta US; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. <i>Haemophilia</i>. 1995;1(suppl 1):8-13.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rossbach HC. Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A. <i>Vasc Health Risk Manag.</i> 2010;6:59-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-drug-information/abstract-text/20234780/pubmed\" target=\"_blank\" id=\"20234780\">20234780</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. <i>Haemophilia</i>. 2013;19(1):e1-e47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-drug-information/abstract-text/22776238/pubmed\" target=\"_blank\" id=\"22776238\">22776238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Varon D, Martinowitz U. Continuous infusion therapy in haemophilia. <i>Haemophilia</i>. 1998;4(4):431-435.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-drug-information/abstract-text/9873771/pubmed\" target=\"_blank\" id=\"9873771\">9873771</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    White GC, Rosendaal F, Aledort LM, et al, &ldquo;Definitions in Hemophilia. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis,&rdquo; <i>Thromb Haemost</i>, 2001, 85(3):560.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-drug-information/abstract-text/11307831/pubmed\" target=\"_blank\" id=\"11307831\">11307831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xyntha (antihemophilic factor [recombinant]) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xyntha (antihemophilic factor [recombinant]) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; May 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9723 Version 188.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F135784\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F135785\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F135799\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F135786\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F135795\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F135787\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15673189\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15673190\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F135770\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F135756\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F25573579\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F135773\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F135772\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6814324\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F135763\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F135776\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F135760\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298758\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6218001\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F135766\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F135778\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20547295\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F3000257\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F135768\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F135771\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F135759\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F135775\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F21121604\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F135779\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9723|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=factor-viii-recombinant-human-patient-drug-information\" class=\"drug drug_patient\">Factor VIII, recombinant human: Patient drug information</a></li><li><a href=\"topic.htm?path=factor-viii-recombinant-human-pediatric-drug-information\" class=\"drug drug_pediatric\">Factor VIII, recombinant human: Pediatric drug information</a></li></ul></div></div>","javascript":null}